Bill & Melinda Gates Foundation Invests $2.5 Billion in Women’s Health Innovation

Women's health remains significantly underflected in global healthcare research and innovation, despite its profound implications for both public health and economic opportunity. A 2021 analysis by McKinsey & Company revealed that only 1% of healthcare research and innovation is dedicated to female-specific conditions outside oncology, while women are also underrepresented in clinical trials for diseases that affect both genders. This lack of attention has left critical conditions like endometriosis, autoimmune diseases, and heavy menstrual bleeding with limited solutions. Endometriosis, for example, affects one in 10 women globally, yet 65% of cases are initially misdiagnosed [1].

The underinvestment in women’s health has tangible consequences. Women, despite living longer than men, spend more time in poor health due to a lack of effective treatments and diagnostic tools tailored to their needs. This disparity is a major focus of the Bill & Melinda Gates Foundation’s gender equality work. Over the past 25 years, the foundation has contributed to significant progress, including a 40% decline in maternal mortality, expanded access to HPV vaccines, and improved contraceptive options. However, more needs to be done. In response, the foundation has committed $2.5 billion over the next five years to advancing women’s health innovation [1].

This initiative is not just a public health imperative but also a compelling business opportunity. McKinsey & Company estimates the market potential for endometriosis treatments alone ranges from $180 billion to $250 billion, comparable to the market for major conditions like diabetes [1]. Innovations such as AI-powered portable ultrasound devices, developed with support from the Gates Foundation, demonstrate the intersection of public health and market viability. These devices, which can detect high-risk pregnancies and gestational age with accuracy, have potential applications in both low-income countries and rural regions in high-income countries, such as parts of the United States where access to maternity care is limited [1].

The FDA’s 2024 approval of the sFIt-1PIGF ratio test for preeclampsia is another step forward. The test, which measures two proteins linked to placental development, offers a more accurate diagnosis and can prevent both unnecessary hospitalizations and life-threatening delays. The Gates Foundation is now supporting efforts to adapt this test for use in low- and middle-income countries [1]. The personal impact of such innovations is evident—foundation staff have already benefited from early detection of preeclampsia through this tool, leading to timely interventions and positive outcomes [1].

The potential for innovation in women’s health is vast. Closing the gap in treatment for nine major conditions could add 27 million years of healthy life per year globally—equivalent to three extra healthy days for every woman annually [1]. While the foundation’s $2.5 billion investment is a significant commitment, it represents only a small portion of what is needed to address these long-standing health disparities. Private sector partners, particularly in biotech, pharmaceuticals, and consumer health, have a crucial role to play. Investing in women’s health is not just socially responsible—it is economically prudent, offering large-scale market opportunities in conditions that affect millions of women across income levels [1].

Source:

[1] Why investing in women’s health is good for business, https://fortune.com/2025/08/04/why-investing-in-womens-health-is-good-for-business/